Hypofyzární adenomy--kam smeruje lécba na pocátku 21. století?
[Pituitary adenomas--where is the treatment heading at the beginning of the 21st century?]
Jazyk čeština Země Česko Médium print
Typ dokumentu anglický abstrakt, časopisecké články, přehledy
PubMed
20842914
- MeSH
- adenom komplikace terapie MeSH
- akromegalie etiologie MeSH
- hypersekrece ACTH v hypofýze etiologie MeSH
- lidé MeSH
- nádory hypofýzy komplikace terapie MeSH
- prolaktinom terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- anglický abstrakt MeSH
- časopisecké články MeSH
- přehledy MeSH
To treat pituitary adenomas, three modes of treatment are usually combined: neurosurgery, radiation and pharmacological. Prolactinomas are an exception with predominantly pharmacological management. Patients with acromegaly are usually diagnosed late and thus many neurosurgeries fail to completely remove the adenoma. Any residual tumour tissue is usually irradiated with the Leksell Gamma Knife, and dopamine agonists, somatostatine analogues or growth hormone receptor antagonists are used to normalize the hormonal hypersecretion until the complete effect of the radiation. The same surgical and Gamma Knife procedures are used in patients with the Cushing's disease and TSH-secreting adenomas. Ketoconazole, metyrapone and cabergoline are used until the radiation effect in the Cushing's disease is complete, similarly, somatostatine analogues are used in TSH-secreting adenomas. Nonfunctional adenomas are less responsive to pharmacological treatment. Proautophagic cytostatic temozolamide has been used in aggressive pituitary adenomas and carcinomas.